Fig. 3

Validation of Ad-Tff2-CTP-Flag activity in AOM/DSS-induced colon cancer model. a, b Ad-Tff2 suppresses colon tumorigenesis in wild-type mice treated with AOM/DSS. a Colon appearance (left), tumor number (right), b number of splenic CD11b⁺Gr-1⁺ cells. Two experiments have been done with 3–4 mice in each group. c, d Ad Tff2-CTP-Flag suppresses colon tumorigenesis in AOM/DSS-induced colon cancer model. c Colon appearance and tumor number, d proportion CD11b⁺Gr-1⁺ cells in the spleen from wild-type mice treated with Ad-Tff2-CTP versus Ad-Fc-CTP, unpaired t-test, *p < 0.05. Two experiments have been done with 3–4 mice in each group. e Overlapping staining for Flag and Gr-1 in the spleen of Tff2-null mice injected with Ad-Tff2-CTP-Flag. Mice were given 2% DSS for 5 consecutive days, then seven days later adenovirus was administrated via tail vein and mice were sacrificed in one week after adenovirus administration. Bar size is 50 µm. f BrdU incorporation in splenic CD11b⁺Gr-1⁺ cells of wild-type mice injected with Ad-Fc-CTP-Flag compare with Ad-Tff2-CTP-Flag, unpaired t-test. Wild-type mice were treated 2% DSS for 5 consecutive days, then on day 7 post treatment with DSS single injection of Ad-Tff2-CTP or Ad-Fc-CTP-Flag (both 5 × 10⁸ pfu) was administered via tail vein injection. Mice were sacrificed on day 19 after start of DSS treatment, BrdU was injected three hours before sacrifice